We are taking part in an international clinical trial to assess the safety and effectiveness of a new treatment for cognitive symptoms of Long COVID

The German laboratory Schwabe has launched the COCOS study, a project aimed at evaluating the safety and effectiveness of a new treatment, the EGB 761 extract from the Ginkgo Biloba plant, to improve cognitive impairments associated with Long COVID. A total of ten centres across Europe are participating, including the Long COVID research line of the Foundation.

Initially, the Foundation committed to recruiting 15 participants. However, the interest and dedication of the team have exceeded expectations, reaching 20 individuals with neurocognitive impairment who are already part of the study.

This progress represents two pieces of good news:

• On the one hand, having new studies that explore therapeutic strategies to tackle this global health issue.
• On the other, the team’s ability to surpass the initial recruitment targets.

The clinical trial is currently underway, and the recruitment process will remain open over the coming months.

The Foundation’s team involved in the study includes Dr Lourdes Mateu as co-principal investigator, Dr Aiello, Dr Lladós, and Dr Santos. The psychology team includes Dr Anna Prats and Dr Jose A. Muñoz-Moreno.

Candidate management and follow-up of both baseline and subsequent visits are coordinated by the clinical trials team at ScienHub, the Foundation’s service platform.

El ensayo clínico está en marcha y el proceso de reclutamiento de participantes permanecerá abierto durante los próximos meses.